Clinical Trial Update: Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating SKB264 for locally advanced, recurrent or metastatic HR+/HER2- breast cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• SKB264

Snippet

Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Conditions: Metastatic Breast Cancer | Phase 3 | Status: RECRUITING